Dynavax Technologies reported $528.93M in Current Liabilities for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Adma Biologics ADMA:US $ 32.34M 14.15M
Alexion Pharmaceuticals ALXN:US $ 1426.2M 198.5M
Amgen AMGN:US $ 14842M 257M
AstraZeneca AZN:LN 23649M 1427M
Astrazeneca AZN:US $ 23649M 1427M
Biogen BIIB:US $ 4211.6M 864.4M
Biomarin Pharmaceutical BMRN:US $ 514.9M 71.55M
Bristol Myers Squibb BMY:US $ 21460M 2469M
Chimerix CMRX:US $ 26.29M 1.37M
Dynavax Technologies DVAX:US $ 528.93M 324.29M
Gilead Sciences GILD:US $ 10245M 31M
Glaxosmithkline GSK:US $ 22417M 1030M
Gw Pharmaceuticals GWPH:US $ 160.25M 0.44M
Idera Pharmaceuticals IDRA:US $ 5.57M 0.46M
Minerva Neurosciences NERV:US $ 3.08M 1.36M
Nektar Therapeutics NKTR:US $ 139.97M 8.95M
Neurocrine Biosciences NBIX:US $ 225.9M 13M
Novartis NOVN:VX SF 29880M 247M
Regeneron Pharmaceuticals REGN:US $ 3714.8M 17.6M
Sarepta Therapeutics SRPT:US $ 373.44M 51.58M
Vertex Pharmaceuticals VRTX:US $ 1914.26M 77.82M